Literature DB >> 24295719

Incidence and outcomes of heparin-induced thrombocytopenia in patients undergoing cardiac surgery in North America: an analysis of the nationwide inpatient sample.

Matthew Seigerman1, Paul Cavallaro1, Shinobu Itagaki1, Insung Chung2, Joanna Chikwe3.   

Abstract

OBJECTIVES: The objective of this study was to quantify the impact of heparin-induced thrombocytopenia (HIT) on outcomes after cardiac surgery.
DESIGN: Retrospective analysis of national database.
SETTING: United States hospitals. PARTICIPANTS: Patients identified from 186,771 discharge records undergoing cardiac surgery from the Nationwide Inpatient Sample between 2009 and 2010.
INTERVENTIONS: None.
MEASUREMENTS AND MAIN RESULTS: Heparin-induced thrombocytopenia was diagnosed in 506 (0.3%), and secondary thrombocytopenia was diagnosed in 16,809 (8.7%). Operative mortality was 11.1% in patients with HIT compared to 4.5% for patients without thrombocytopenia (p<0.001) and 4.0% for patients with a diagnosis of secondary thrombocytopenia (p<0.001). After adjusting for baseline patient comorbidity, the strongest independent predictors of HIT in patients undergoing cardiac surgery were female gender (OR 1.4, 95% confidence interval [CI] 1.28-1.48), congestive heart failure (OR 1.8, 95% CI 1.71-1.98), cardiac insufficiency (OR 2.2, 95% CI 1.97-2.39), atrial fibrillation (OR 1.4, 95% CI 1.30-1.51), liver disease (OR 2.2, 95% CI 1.96-2.50), and chronic renal failure (OR 1.4, 95% CI 1.30-1.51). HIT was associated with significantly increased risk of major adverse postoperative outcomes including death (OR 1.5, 95% CI 1.3-1.7), stroke (OR 2.4, 95% CI 1.9-3.1), amputation (OR 7.46, 95% CI 4.0-14.0), and acute renal failure (OR 2.3, 95% CI 2.1-2.5), respiratory failure (OR 1.9, 95% CI 1.8-2.1), and need for tracheostomy (OR 2.7, 95% CI 2.3-3.1).
CONCLUSIONS: Heparin-induced thrombocytopenia is associated with a 50% increase in early mortality, and most patients with this diagnosis experience major postoperative morbidity or functional deficits.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  HIT; cardiac surgery; complications; heparin; platelets; thrombocytopenia

Mesh:

Substances:

Year:  2013        PMID: 24295719     DOI: 10.1053/j.jvca.2013.07.021

Source DB:  PubMed          Journal:  J Cardiothorac Vasc Anesth        ISSN: 1053-0770            Impact factor:   2.628


  6 in total

1.  Bivalirudin fails to prevent atrial thrombus development in heparin-induced thrombocytopaenia and thrombosis syndrome.

Authors:  Alexandru Topliceanu; Thomas Breen; Hiren Patel; Neil Yager; Erica Maceira; Mikhail Torosoff
Journal:  BMJ Case Rep       Date:  2018-10-14

2.  Characterization of hospitalized cardiovascular patients with suspected heparin-induced thrombocytopenia.

Authors:  Felicitas Stoll; Miriel Gödde; Albrecht Leo; Hugo A Katus; Oliver J Müller
Journal:  Clin Cardiol       Date:  2018-12-03       Impact factor: 2.882

3.  Safety and economic considerations of argatroban use in critically ill patients: a retrospective analysis.

Authors:  Se-Chan Kim; Nicole Tran; Jens-Christian Schewe; Olaf Boehm; Maria Wittmann; Ingo Graeff; Andreas Hoeft; Georg Baumgarten
Journal:  J Cardiothorac Surg       Date:  2015-02-07       Impact factor: 1.637

4.  Profiling Heparin-Induced Thrombocytopenia (HIT) Antibodies in Hospitalized Patients With and Without Diabetes.

Authors:  Margaret Prechel; Susan Hudec; Elizabeth Lowden; Vicki Escalante; Nicholas Emanuele; Maryann Emanuele; Jeanine M Walenga
Journal:  Clin Appl Thromb Hemost       Date:  2018-11-12       Impact factor: 2.389

5.  Risk Factors in Hospitalized Patients for Heparin-Induced Thrombocytopenia by Real World Database: A New Role for Primary Hypercoagulable States.

Authors:  Jasmeet Kaur; Camelia Arsene; Sumeet Kumar Yadav; Olusola Ogundipe; Ambreen Malik; Anupam Ashutosh Sule; Geetha Krishnamoorthy
Journal:  J Hematol       Date:  2020-08-04

6.  Heparin-induced thrombocytopenia in patients readmitted after open cardiac surgical procedures: A case series.

Authors:  Michael A Catalano; Vikram Prasad; Alexander M Spring; Hugh Cassiere; Tylis Y Chang; Alan Hartman; Pey-Jen Yu
Journal:  JTCVS Open       Date:  2020-08-03
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.